A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Clinical trial NCT05271409 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05271409
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-30
- Primary completion
- 2025-11-20
- Enrollment
- 152
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.